Article
FLT3 inhibitors as MRD-guided salvage treatment for molecular failure in FLT3 mutated AML.
Leukemia - 1 Oct 2023
Othman Jad, Potter Nicola, Mokretar Katya, Taussig David, Khan Anjum, Krishnamurthy Pramila, Latif Anne-Louise, Cahalin Paul, Aries James, Amer Mariam, Belsham Edward, Conneally Eibhlin, Craddock Charles, Culligan Dominic, Dennis Mike, Duncan Caroline, Freeman Sylvie D, Furness Caroline, Gilkes Amanda, Gkreka Paraskevi, Hodgson Katherine, Ingram Wendy, Jain Manish, King Andrew, Knapper Steven, Kottaridis Panagiotis, McMullin Mary Frances, Mohite Unmesh, Ngu Loretta, O'Nions Jenny, Patrick Katharine, Rider Tom, Roberts Wing, Severinsen Marianne Tang, Storrar Neill, Taylor Tom, Russell Nigel H, Dillon Richard
Abstract excerpt
Patients with FLT3-mutated AML have a high relapse rate and suboptimal outcomes. Many have co-mutations suitable for measurable residual disease (MRD) monitoring by RT-qPCR and those destined to relapse can be identified by high or rising levels of MRD, called molecular failure. This provides a window for pre-emptive intervention, but there is little evidence to guide treatment. The use of FLT3 inhibitors (FLT3i)...
Topics
- Humans
- fms-Like Tyrosine Kinase 3
- Leukemia, Myeloid, Acute
- Mutation
- Neoplasm Recurrence, Local
- Prospective Studies
- Protein Kinase Inhibitors